Kenneth E. Gonsalves, Craig R. Halberstadt, Cato T. Laurencin, Lakshmi S. Nair. Biomedical Nanostructures
Подождите немного. Документ загружается.
50. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78:110.
51. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable
polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:120.
52. Chawla JS and Amiji MM. Biodegradable poly(o-caprolactone) nanoparticles for
tumor targeted delivery of tamoxifen. Int J Pharm 2002;249:127138.
53. Perez C, et al. Poly(lactic acid)poly(ethylene glycol) nanoparticles as new carriers
for the delivery of plasmid DNA. J Control Release 2001;75:211224.
54. Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of
nanoparticles based on doxorubicinPLGA conjugates. J Control Release
2000;68:419431.
55. Mu
¨
ller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug
formulations in therapy: rationale for development and what we can expect for
the future. Adv Drug Deliv Rev 2001;47:319.
56. Vila A, Sanchez A, Tobo M, Calvo P, Alonso MJ. Design of biodegradable
particles for protein delivery. J Control Release 2002;78:1524.
57. Zhang Z and Feng SS. The drug encapsulation efficiency, in vitro drug release,
cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)tocopheryl
polyethylene glycol succinate nanoparticles. Biomaterials 2006;27:40254033.
58. Liu M, Dong J, Yang Y, Yang X, Xu H. Characterization and release of
triptolide-loaded poly (
D,L-lactic acid) nanoparticles. Eur Polym J 2005;41:
375382.
59. Yamazaki N, et al. Endogenous lectins as targets for drug delivery. Adv Drug
Deliv Rev 2000;43:225 244.
60. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and
diagnosis. Adv Drug Deliv Rev 2002;54:631651.
61. Peracchia MT, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intra-
venous administration and splenic targeting. J Control Release 1999;60:121128.
62. Couvreur P, Gref R, Andrieux K, Malvy C. Nanotechnologies for drug delivery
application to cancer and autoimmune diseases. Prog Solid State Chem 2006;
34:231235.
63. Kaul G and Amiji M. Biodistribution and targeting potential of polyethylene
glycol- modified gelatin nanoparticles in subcutaneous murine tumor model. J
Drug Target 2004;12:585591.
64. Kaul G and Amiji M. Tumor targeted gene delivery using polyethylene glycol-
modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005;
22(6):951961.
65. Li YP, et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor
carriers: pharmacokinetics and anti-tumor effects. Biol Pharm Bull 2001;24(6):
662665.
66. Vittaz M, et al. Effect of PEO surface density on long circulating PLAPEO
nanoparticles which are very low complement activators. Biomaterials 1996;17:
15751581.
67. Zeng Y and Pitt WG. Poly(ethylene oxide)-b-poly(N-isopropylacrylamide)
nanoparticles with crosslinked cores as drug carriers. J Biomater Sci Polym Ed
2005;16(3):371380.
186
BIOMEDICAL NANOSTRUCTURES
68. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(b-amino
ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of
hydrophobic drugs. Part I. In Vitro evaluations. Mol Pharmacol 2005;2(5): 357366.
69. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv
Rev 2001;47:6581.
70. Roney C, et al. Targeted nanoparticles for drug delivery through the bloodbrain
barrier for Alzheimer’s disease. J Control Release 2005;108:193214.
71. Garcia EG, Andrieux K, Gil S, Couvreur P. Colloidal carriers and bloodbrain
barrier translocation: a way to deliver drugs to the brain. Int J Pharm 2005;298:
274292.
72. Olivier JC. Drug transport to brain with targeted nanoparticles. J Am Soc Exp
Neurother 2005;2:108119.
73. Gao X, et al. Lectin-conjugated PEGPLA nanoparticles: preparation and brain
delivery after intranasal administration. Biomaterials 2006;27:34823490.
74. Gao K and Jiang X. Influence of particle size on transport of methotrexate across
bloodbrain barrier by polysorbate 80-coated polybutylcyanoacrylate nanopar-
ticles. Int J Pharm 2006;310:213219.
75. Michaelis K, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles
strongly enhances drug transport into the brain. J Pharm Exp Ther 2006;317(3):
12461253.
76. Mishra V, et al. Targeted brain delivery of AZT via transferrin anchored pegylated
albumin nanoparticles. J Drug Target 2006;14(1):4553.
77. Costantino L, et al. Peptide-derivatized biodegradable nanoparticles able to cross
the bloodbrain barrier. J Control Release 2005;108:8496.
78. Lu W, et al. Cationic albumin-conjugated pegylated nanoparticles as novel drug
carrier for brain delivery. J Control Release 2005;107:428448.
79. Krauzewicz N, et al. Virus-like gene transfer into cells mediated by polyomavirus
pseudocapsids. Gene Ther 2000;7:21222131.
80. Leong KW, et al. DNApolycation nanospheres as non-viral gene delivery
vehicles. J Control Release 1998;53:183193.
81. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52:145150.
82. Mansouri S, et al. ChitosanDNA nanoparticles as non-viral vectors in gene
therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm
2004;57:18.
83. Zhao X, Yu SB, Wu FN, Mao ZB, Yu CL. Transfection of primary chondro-
cytes using chitosanpEGFP nanoparticles. J Control Release 2006;112:
223228.
84. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral
gene delivery systems. Eur J Pharm Biopharm 2005;60:247266.
85. Santos AG, et al. Oligonucleotidepolyethylenimine complexes targeting retinal
cells: structural analysis and application to anti-TGFb-2 therapy. Pharm Res
2006;23(4):770781.
86. Guliyeva U, Oner F, Ozsoy S, Haziroglu R. Chitosan microparticles containing
plasmid
DNA
as potential oral gene delivery system. Eur J Pharm Biopharm
2006;62:1725.
DEVELOPMENT OF NANOSTRUCTURES FOR DRUG DELIVERY APPLICATIONS 187
87. Silva GA. Introduction to nanotechnology and its applications to medicine. Surg
Neurol 2004;61:216220.
88. Yokoyama A, et al. Biological behaviour of hat stacked carbon nanofibers in
subcutaneous tissue in rats. Nano Lett 2005;5(1):157161.
89. Chen Z, et al. Structure of poly(ferrocenyldimethylsilane) in electrospun
organometallic nanofibers. Macromolecules 2001;34(18):61646166.
90. Kameoka J, Verbridge SS, Lui H. Fabrication of suspended silica glass nanofibers
using a scanned electrospinning source. Nano Lett 2004;4(11):21052108.
91. Zhang M, Bando Y, Wada K, Kurashima K. Synthesis of nanotubes and
nanowires of silicon oxide. J Mater Sci Lett 1999;18(23):19111913.
92. Duncan R. The drawing era of polymer therapeutics. Nat Rev Drug Discov
2003;2:347360.
93. Griffith LG. Polymeric biomaterials. Acta Mater 2000;48:263277.
94. Zhang Y, Lim CT, Ramakrishna S, Huang ZM. Recent development of polymer
nanofibers for biomedical and biotechnological applications. J Mater Sci-Mater
Med 2005;16:933946.
95. Ondarcuhu T and Joachim C. Drawing a single nanofiber over hundreds of
microns. Eur Phys Lett 1998;42:215220.
96. Thomson RC, Shung AK, Yaszemski MJ, Mikos AG. Polymer scaffold
processing. In:Vacanti J, Lanza RP, Langer R, editors. Principles of Tissue
Engineering. San Diego: Academic Press; 251261.
97. Feng L, Li SJ, Song YL, Jiang L, Zhu DB. Template based synthesis of aligned
polyacryonitrile nanofibers using a novel extrusion method. Synth Met 2003;
136:817818.
98. Martin CR. Template synthesis of electronically conductive polymer nanostruc-
tures. Acc Chem Res November:1995;28:6168.
99. Martin CR. Membrane-based synthesis of nanomaterials. Chem Mater 1996;8:
17391746.
100. Martin CR and Hulteen JC. A general template-based method for the preparation
of nanomaterials. J Mater Chem 1997;7:10751087.
101. Guler MO, Claussen RC, Stupp SI. Encapsulation of pyrene within self-assembled
peptide amphiphile nanofibers. J Mater Chem 2005;15:45074512.
102. Chen P. Self-assembly of ionic-complementary peptides: a physicochemical
viewpoint. Colloids Surf A: Physicochem Eng Aspects 2005;261:324.
103. Hartgerink JD, Beniash E, Stupp SI. Peptide-amphiphile nanofibers: a versatile
scaffold for the preparation of self-assembling materials. Proc Natl Acad Sci USA
2002;99(8):51335138.
104. Hartgerink JD, Paramonov SE, Jun HW. Self-assembly of peptide-amphiphile
nanofibers: the roles of hydrogen bonding and amphiphilic packing. J Am Chem
Soc 2006;128:72917298.
105. Niece KL, Hartgerink JD, Donners JM, Stupp SI. Self-assembly combining two
bioactive peptide-amphiphile molecules into nanofibers by electrostatic attraction.
J Am Chem Soc 2003;125:71467147.
106. Ma PX and Zhang R. Synthetic nano-scale fibrous extracellular matrix. J Biomed
Mater Res 1999;46:60 72.
188
BIOMEDICAL NANOSTRUCTURES
107. Frenot A and Chronakis IS. Polymer nanofibers assembled by electrospinning.
Curr Opin Colloid Interface Sci 2003;8:6475.
108. Reneker DH and Chun I. Nanometre diameter fibres of polymer, produced by
electrospinning. Nanotechnology 1996;7:216223.
109. Inai R, Kotaki M, Ramakrishna S. Structure and properties of electrospun PLLA
single nanofibers. Nanotechnology 2005;16:208213.
110. Li M, et al. Electrospun protein fibers as matrices for tissue engineering.
Biomaterials 2005;26:59996008.
111. Smith LA and Ma PX. Nano-fibrous scaffolds for tissue engineering. Colloids Surf
B Biointerfaces 2004;39:125131.
112. Vasita R and Katti DS. Nanofibers and their applications in tissue engineering. Int
J Nanomed 2006;1(1):1530.
113. Shorey JD and Michelson D. On the mechanism of electrospraying. Nucl Instrum
Methods 1970;82:295296.
114. Xinhua Zong X, et al. Structure and process relationship of electrospun
bioabsorbable nanofiber membranes. Polymer 2002;43:44034412.
115. Huang ZM, Zhang YZ, Kotaki M, Ramakrishna S. A review on polymer
nanofibers by electrospinning and their applications in nanocomposites. Compos
Sci Technol 2003;63:22232253.
116. Kosmider K and Scott J. Polymeric nanofibers exhibit an enhanced air filtration
performance. Filtr Sep 2002;39(6):2022.
117. Gibson HL, Truong Q, Walker JD, Jones WE. Chemical and biological protection
and detection in fabrics for protective clothing. Mater Res Soc 2003;228(8):
123128.
118. Pham QP, Sharma U, Mikos AG. Electrospinning of polymeric nanofibers for
tissue engineering applications: a review. Tissue Eng 2006;12(5):11971211.
119. Salvay DM and Shea LD. Inductive tissue engineering with protein and DNA-
releasing scaffolds. Mol Biosyst 2006;2:3648.
120. Kenawy ER, et al. Release of tetracycline hydrochloride from electrospun
poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release
2002;81:5764.
121. Zeng J, et al. Biodegradable electrospun fibers for drug delivery. J Control Release
2003;92:227231.
122. Kim K, et al. Incorporation and controlled release of a hydrophilic antibiotic using
poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control
Release 2004;98:4756.
123. Cui W, et al. Investigation of drug release and matrix degradation of electrospun
poly(
DL-lactide) fibers with paracetanol inoculation. Biomacromolecules 2006;7:
16231629.
124. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresorbable nanofiber-
based systems for wound healing and drug delivery: optimization of fabrication
parameters. J Biomed Mater Res B Appl Biomater 70(2):286296.
125. Verreck G, et al. Incorporation of drugs in an amorphous state into electrospun
nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control
Release 2003;92:349360.
DEVELOPMENT OF NANOSTRUCTURES FOR DRUG DELIVERY APPLICATIONS 189
126. Rosen HB, Chang J, Wnek GE, Linhardt RJ, Langer R. Bioerodible
polyanhydrides for controlled drug delivery. Biomaterials 1983;4:131133.
127. Taepaiboon P, Rungsardthong U, Supaphol P. Drug-loaded electrospun mats of
poly(vinyl alcohol) fibres and their release characteristics of four model drugs.
Nanotechnology 2006;17:23172329.
128. Huang ZM, et al. Encapsulating drugs in biodegradable ultrafine fibers through
co-axial electrospinning. J Biomed Mater Res 2006;77:169179.
129. Sun Z, et al. Compound coreshell nanofibers by coelectrospinning. Adv Mater
2003;15(22):19291932.
130. Jiang H, et al. Preparation and characterization of ibuprofen-loaded poly(lactide-
co-glycolide)/poly(ethylene glycol)-g-chitosan electrospun membranes. J Biomater
Sci Polym Ed 2004;15(3):279296.
131. Luu YK, Kim K, Hsiao BS, Chu B, Hadjiargyrou M. Development of a
nanostructured DNA delivery scaffold via electrospinning of PLGA and
PLAPEG block copolymers. J Control Release 2003;89:341353.
132. Liang D, et al. In vitro non-viral gene delivery with nanofibrous scaffolds. Nucleic
Acids Res 2005;33(19):18.
133. Zeng J, et al. Poly(vinyl alcohol) nanofibers by electrospinning as a protein
delivery system and the retardation of enzyme release by additional polymer
coatings. Biomacromolecules 2005;6:14841488.
134. Jiang H, et al. A facile technique to prepare biodegradable coaxial electrospun
nanofibers for controlled release of bioactive agents. J Control Release 2005;108:
237243.
135. Jiang H, Fang D, Hsiao BS, Chu B, Chen W. Optimization and characterization of
dextran membranes prepared by electrospinning. Biomacromolecules 2004;5:
326333.
136. Vasita R and Katti DS. Growth factor-delivery systems for tissue engineering: a
materials perspective. Expert Rev Med Devices 2006;1:2947.
137. Chew SY, Wen J, Yim EF, Leong KW. Sustained release of proteins from
electrospun biodegradable fibers. Biomacromolecules 2005;6:20172024.
138. Beaty CE and Saltzman MW. Controlled growth factor delivery induces
differential neurite outgrowth in three-dimensional cell cultures. J Control
Release 1993;24:1523.
139. Elbert SS and Hubbell JA. Controlled release of nerve growth factor from a
heparin-containing fibrin-based cell ingrowth matrix. J Control Release 2000;
69:149158.
140. Lee AC, et al. Controlled release of nerve growth factor enhances sciatic nerve
regeneration. Exp Neurol 2003;184:295303.
141. Haller MF and Saltzman MW. Nerve growth factor delivery systems. J Control
Release 1998;53:16.
142. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth
factors for bone repair. Eur J Pharm Biopharm 2004;58:197208.
143. Holland TA, Tabata Y, Mikos AG. Dual growth factor delivery from degradable
oligo(poly(ethyleneglycol) fumarate) hydrogel scaffolds for cartilage tissue
engineering. J Control Release 2005;101:111125.
190
BIOMEDICAL NANOSTRUCTURES
144. Simmons CA, Alsberg E, Hsiong S, Kim WJ, Mooney DJ. Dual growth factor
delivery and controlled scaffold degradation enhance in vivo bone formation by
transplanted bone marrow stromal cells. Bone 2004;35:562569.
145. Wei G, Jin Q, Giannobile WV, Ma PX. Nano-fibrous scaffold for controlled
delivery of recombinant human PDGF-BB. J Control Release 2006;112:
103110.
146. Lee JY, et al. Enhanced bone formation by controlled growth factor delivery from
chitosan-based biomaterials. J Control Release 2002;78:187197.
147. Park YJ, et al. Controlled release of platelet-derived growth factor-BB from
chondroitin sulfatechitosan sponge for guided bone regeneration. J Control
Release 2000;67:385394.
148. Markkanen JE, Rissanen TT, Antti Kivel A, Herttuala SY. Growth factor-
induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy.
Cardiovasc Res 2005;65:656664.
149. Sun Q, et al. Sustained vascular endothelial growth factor delivery enhances
angiogenesis and perfusion in ischemic hind limb. Pharm Res 2005;22(7):
11101116.
150. Frechet JMJ and Tomalia D. Dendrimers and Other Dendritic Polymers. New
York: John Wiley & Sons, Inc.; 2001.
151. Newkome GR, Moorefield CN, Vogtle F. Dendrimers and Dendrons: Concepts,
Syntheses, Applications. Wiley-VCH; 2002.
152. Tomalia DA. Starburst dendrimersnanoscopic supermolecules according to
dendritic rules and principles. Macromol Symp 1996;101:243255.
153. Hawker CJ and Frechet JMJ. Preparation of polymers with controlled molecular
architecturea new convergent approach to dendritic macromolecules. J Am
Chem Soc 1990;112:76387647.
154. Esfand R and Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from
biomimicry to drug delivery and biomedical applications. Drug Discov Today
2001;6:427436.
155. Gillies ER and Frechet JMJ. Dendrimers and dendritic polymers in drug delivery.
Drug Discov Today 2005;10:3543.
156. Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical
properties and applications. Chem Rev 1999;99:16651688.
157. Liu M and Frechet JMJ. Designing dendrimers for drug delivery. Pharm Sci
Technol Today 1999;2(10):393401.
158. Duncan R. Polymer conjugates for tumour targeting and intra-cytoplasmic
delivery. the EPR effect as a common gateway? Pharm Sci Technol Today
1999;2:441449.
159. Available at www.dekker.com/sdek/93432345-48443502/.
160. Svenson S and Tomalia DA. Dendrimers in biomedical applicationsreflections
on the field. Adv Drug Deliv Rev 2005;57:21062129.
161. Dufs C, Uchegbu IF, Schtzlein AG. Dendrimers in gene delivery. Adv Drug Deliv
Rev 2005;57:21772202.
162. Klajnert B and Bryszewska M. Dendrimers: properties and applications. Acta
Biochim Pol 2001;48:199208.
DEVELOPMENT OF NANOSTRUCTURES FOR DRUG DELIVERY APPLICATIONS 191
163. Beezer AE, et al. Dendrimers as potential drug carriers; encapsulation of acidic
hydrophobes within water-soluble PAMAM derivatives. Tetrahedron 2003;59:
38733880.
164. Patri AK, et al. Targeted drug delivery with dendrimers: comparison of the release
kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Adv Drug Deliv Rev 2005;57:22032214.
165. Malik N, Evagorou EG, Duncan R. Dendrimerplatinate: a novel approach to
cancer chemotherapy. Anticancer Drugs 1999;10(8):767776.
166. Zhuo RX, Du B, Lu ZR. In vitro release of 5-fluorouracil with cyclic core dendritic
polymer. J Control Release 1999;57:249255.
167. Marie RG. Epidemiology of nonsteroidal anti-inflammatory drug-associated
gastrointestinal injury. Am J Med 1998;104:2329.
168. Denis MM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J
Med 1999;107:3741.
169. Kolhe P, et al. Preparation, cellular transport, and activity of polyamidoamine-
based dendritic nanodevices with a high drug payload. Biomaterials 2006;27:
660669.
170. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in
vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J
Pharm 2003;259:143160.
171. Yiyun C and Tongwen X. Dendrimers as potential drug carriers, Part I.
Solubilization of non-steroidal anti-inflammatory drugs in the presence of
polyamidoamine dendrimers. Eur J Med Chem 2005;40:11881192.
172. Na M, et al. Dendrimers as potential drug carriers. Part II. Prolonged delivery of
ketoprofen by in vitro and in vivo studies. Eur J Med Chem 2006;41:670674.
173. Bielinska AU, et al. Regulation of in vitro gene expression using antisense
oligonucleotides or antisense expression plasmids transfected using starburst
PAMAM dendrimers. Nucleic Acids Res 1996;24:21762182.
174. Kukowska-Latallo JF, et al. Intravascular and endobronchial DNA delivery to
murine lung tissue using a novel, nonviral vector. Hum Gene Ther 2000;11:
13851395.
175. Eichman JD, Bielinska AU, Latallo JK, Baker JR. The use of PAMAM
dendrimers in the efficient transfer of genetic material into cells. Pharm Sci
Technol Today 2000;3(7):232245.
176. Haensler J and Szoka FC. Polyamidoaminecascade polymers mediate efficient
transfection of cells in culture. Bioconjug Chem 1993;4:372379.
177. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug
Deliv Rev 2005;57:2177 2202.
178. Dhanikula RS and Hildgen P. Synthesis and evaluation of novel dendrimers with a
hydrophilic interior as nanocarriers for drug delivery. Bioconjug Chem 2006;
17:2941.
179. Bhadra D, Bhadra S, Jain NK. PEGylated peptide based dendritic nanoparticulate
systems for delivery of artemether. J Drug Deliv Sci Technol 2005;15:6573.
180. Ostro MJ and Cullis PR. Use of liposomes as injectable-drug delivery systems. Am
J Hosp Pharm 1989;46:15761587.
192
BIOMEDICAL NANOSTRUCTURES
181. Available at http://en.wikipedia.org/wiki/Liposome.
182. Kshirsagar NA. Drug delivery systems. Indian J Pharma 2000;32:5461.
183. Bangham AD and Horne RW. Negative staining of phospholipids and their
structural modification by surface-active agents as observed in the electron
microscope. J Mol Biol 1964;8:660668.
184. Lasic DD. Novel applications of liposomes. Tibtech 1998;16:307321.
185. Diederichs JE and Mu
¨
ller RH. Liposomen in kosmetika und arzneimitteln. Pharm
Ind 1994;56:267275.
186. Heath TD. Liposome dependent drugs. In:Gregoriadis G, editor. Liposomes as
Drug Carriers: Trends and Progress. New York: John Wiley & Sons, Inc.; 1988.
p 709718.
187. Allemann E, Gurny R, Doelker E. Drug loaded nanoparticlespreparation
methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:173191.
188. Smith A and Hunneyball IM. Evaluation of polylactide as a biodegradable drug
delivery system for parenteral administration. Int J Pharm 1986;30:215230.
189. Siekmann B and Westesen K. Sub-micron sized parenteral carrier systems based
on solid lipids. Pharm Pharmacol Lett 1992;1:123126.
190. Schwarz C, Mehnert W, Lucks JS, Mu
¨
ller RH. Solid lipid nanoparticles (SLN) for
controlled drug delivery. I. Production, characterization and sterilization. J
Control Release 1994;30:8396.
191. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid
nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 1993;
93:189199.
192. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental
factors on the production process of solid lipid nanoparticles. Eur J Pharm
Biopharm 1996;43(2):110115.
193. Mu
¨
ller RH, et al. Solid lipid nanoparticles (SLN) as an alternative colloidal carrier
system for controlled drug delivery. Eur J Pharm Biopharm 1995;41(1):6269.
194. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic
transitions in triglyceride nanoparticles. Int J Pharm 1996;129:159173.
195. Gasco MR. Solid lipid nanospheres from warm microemulsions. Pharm Technol
Eur 1997;9(11):5258.
196. Heiati H, Phillips NC, Tawashi R. Evidence for phospholipids bilayer formation
in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm
Res 1996;13(9):14061410.
197. Vringer T and Ronde HG. Preparation and structure of a water-in-oil cream
containing lipid nanoparticles. J Pharm Sci 1995;84(4):466472.
198. Sjostrom B, Kaplun A, Talmon Y, Cabane B. Structure of nanoparticles prepared
from oil-in-water emulsions. Pharm Res 1995;12(1):3948.
199. Dingler A, Blum RP, Niehus H, Gohla S, Mu
¨
ller RH. Solid lipid nanoparticles
(SLN/Lipopearls): a pharmaceutical and cosmetic carrier for the application of
vitamin E in dermal products. J Microencapsul 1999;16(6): 751767.
200. Demirel M, Yazan Y, Mu
¨
ller RH, Kilic F, Bozan B. Formulation and in
vitroin vivo evaluation of piribedil solid lipid particles. J Microencapsul 2001;
18(3):359371.
DEVELOPMENT OF NANOSTRUCTURES FOR DRUG DELIVERY APPLICATIONS 193
201. Wissing SA and Mu
¨
ller RH. Solid lipid nanoparticles as carrier for sunscreens: in
vitro release and in vivo skin penetration. J Control Release 2002;81:225233.
202. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin.
Int J Pharm 1993;89:912.
203. Morel S, Gasco MR, Cavalli R. Incorporation in lipospheres of [
D-Trp-6]LHRH.
Int J Pharm 1994;105:13.
204. Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone MF. Preparation and
evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J
Pharm 1995;117:243246.
205. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G.
Bioavailability of diazepam from aqueous-organic solution, submicron emulsion
and solid lipid nanoparticles after rectal administration to rabbits. Eur J Pharm
Biopharm 2001;52:159163.
206. Mu
¨
ller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
Adv Drug Deliv Rev 2002;54:131155.
207. Mu
¨
ller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved
microencapsulation of drugs. Int J Pharm 2002;242:121 128.
208. Radtke M and Mu
¨
ller RH. Comparison of structural properties of solid lipid
nanoparticles (SLN) versus other lipid particles. Proc Int Symp Control Release
Bioact Mater 2000;27:309310.
209. Olbrich C, Gebner A, Kayser O, Mu
¨
ller RH. Lipiddrug conjugate (LDC)
nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug
diminazenediaceturate. J Drug Target 2002;10(5):387396.
210. Mu
¨
ller RK, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled
drug deliverya review of the state of the art. Eur J Pharm Biopharm
2005;50:161177.
211. Hoffman RM, Margolis LB, Bergelson LD. Binding and entrapment of high
molecular weight DNA by lecithin liposomes. FEBS Lett 1978;33:365368.
212. Ridder M, Wang Y, Hofschneider PH. Liposomes as gene carriers: efficient trans-
formation of mouse L cells by thymidine kinase gene. Science 1982;215:166168.
213. Liu F, Yang J, Huang L, Liu D. Effect of non-ionic surfactants on the formation
of DNA/emulsion complex and the emulsion-mediated gene transfer. Pharm Res
1997;13:16421646.
214. Watwe RM and Bellare JR. Manufacture of liposomes: a review. Curr Sci
1995;68:715724.
215. Cortesi R, Esposito E, Luca G, Nastruzzi C. Production of lipospheres as carriers
for bioactive compounds. Biomaterials 2002;23:22832294.
216. Lim SJ and Kim CK. Formulation parameters determining the physicochemical
characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J
Pharm 2002;243:135146.
217. Siekmann B, Bunjes H, Koch MHJ, Westesen K. Preparation and structural
investigations of colloidal dispersions prepared from cubic monoglyceridewater
phases. Int J Pharm 2002;244:3343.
218. Lippacher A, Mu
¨
ller RH, Mader K. Preparation of semisolid drug carriers for
topical application based on solid lipid nanoparticles. Int J Pharm 2001;214:912.
194
BIOMEDICAL NANOSTRUCTURES
219. Lippacher A, Mu
¨
ller RH, Mader K. Semisolid SLN dispersions for topical
application: influence of formulation and production parameters on microstruc-
ture. Eur J Pharm Biopharm 2002;53(2):155160.
220. Jenning V, Lippacher A, Gohla SH. Medium scale production of solid lipid
nanoparticles (SLN) by high pressure homogenization. J Microencapsul
2002;19(1):110.
221. Dingler A and Gohla S. Production of solid lipid nanoparticles (SLN): scaling up
feasibilities. J Microencapsul 2002;19(1):1116.
222. Cavalli R, Caputo O, Marengo E, Pattarino F, Gasco MR. The effect of the
components of microemulsions on both size and crystalline structure of solid lipid
nanoparticles (SLN) containing a series of model molecules. Pharmazie
1998;53:392396.
223. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and congealed lipid
micropellets and characterisation of their surface morphology by scanning electron
microscopy. Pharm Res 1991;8:4754.
224. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3V,5V-
dioctanoyl-5-fluoro-2V-deoxyuridine and incorporation into solid lipid
nanoparticles. Eur J Pharm Biopharm 2002;54:285290.
225. Hou DZ, Xie CS, Huang KJ, Zhu CH. The production and characteristics of solid
lipid nanoparticles. Biomaterials 2003;24:17811785.
226. Cortesi R, Esposito E, Luca G, Nastruzzi C. Production of lipospheres as carriers
for bioactive compounds. Biomaterials 2002;23:22832294.
227. Shahgaldian P, Silva ED, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-
calix-arene based solid lipid nanoparticles (SLN): a detailed study of preparation
and stability parameters. Int J Pharm 2003;253:2338.
228. Dubes A, et al. Scanning electron microscopy and atomic force microscopy
imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J
Pharm Biopharm 2003;55:279282.
229. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a
comparative review. J Clin Pharmacol 1998;38:58392.
230. Gray A and Morgan J. Liposomes in hematology. Blood Rev 1991;5:258271.
231. Longuet P, et al. Limited protection by small unilamellar liposomes against the
renal tubular toxicity induced by repeated amphotericin B infusion in rats.
Antimicrob Agents Chemother 1991;35:13031308.
232. Davidson RN, et al. Liposomal amphotericin B in drug-resistant leishmaniasis.
Lancet 1991;337:10611062.
233. Gregoriadis G, Gursel I, Gursel M, McCormack B. Liposomes as immunological
adjuvants and vaccine carriers. J Control Release 1996;41:4956.
234. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems.
Biotechnology 1995;13:527537.
235. Oussoren C and Storm G. Targeting to lymph nodes by subcutaneous administra-
tion of liposomes. Int J Pharm 1998;162:3944.
236. Gregoriadis G, Saffie R, DaSouza JB. Liposome mediated DNA vaccination.
FEBS Lett 1997;402:107110.
237. Kim CK and Jeong EJ. Development of dried liposome as effective
immuno-adjuvant for hepatitis B surface antigen. Int J Pharm 1995;115:193199.
DEVELOPMENT OF NANOSTRUCTURES FOR DRUG DELIVERY APPLICATIONS 195